

| Name | Project Title | Institution | Total |
|----------------------|--|---|-------------|
| A/Pr Rachael Morton | Can Symptom monitoring With Feedback to clinicians improve the lives of people on dialysis? (SWIFT) | The University of Sydney | \$1,732,011 |
| Dr Catherine Bell | Can patient-led surveillance detect recurrent or new primary melanoma & reduce need for routinely scheduled follow-up? A Randomised Controlled Trial. | The University of Sydney | \$1,229,190 |
| Prof Janette Vardy | CHALLENGE: Colon Health And Life Long Exercise ChaNGE | The University of Sydney | \$1,121,891 |
| Prof Vanessa Hayes | Establishing a Genomic Signature for High-Risk Prostate Cancer | The University of Sydney | \$1,093,596 |
| A/Pr Paul Timpson | Tailored priming of pancreatic cancer progression and metastatic targeting using KD025, a phase II (ROCK2) inhibitor: fine-tuning treatment via single cell intravital imaging | Garvan Institute of Medical Research | \$892,362 |
| Prof Philip Hansbro | Development of new therapies for COPD | University of Newcastle | \$886,504 |
| A/Pr Anne Cust | A national risk-stratified melanoma screening program in Australia: a modelling study of the benefits, harms, cost-effectiveness and resource implications | The University of Sydney | \$839,351 |
| Prof Patrick Brennan | MY RISC (MammographY: Robust InterrogationS and Calculations): Breast Cancer Prediction Transformed | The University of Sydney | \$814,170 |
| Prof Herbert Herzog | Central control of diet induced thermogenesis | Garvan Institute of Medical Research | \$782,520 |
| Dr Marina Pajic | "Fine-tuned" manipulation of the c-MET oncogenic pathway in pancreatic cancer: a new paradigm of personalised medicine. | Garvan Institute of Medical Research | \$707,521 |
| Dr David Croucher | Complex epistasis between JNK and PI3K pathway mutations in breast cancer. | Garvan Institute of Medical Research | \$686,653 |
| A/Pr Lenka Munoz | Targeting MK2 to overcome glioblastoma resistance to therapy | The University of Sydney | \$667,029 |
| Mr Nicholas Keilar | IRIIS - 2018 | Centenary Institute of Cancer Medicine and Cell Biology | \$403,548 |
| Dr Zaklina Kovacevic | Inhibiting the oncogenic cross-talk between cancer cells and surrounding stroma by targeting the metastasis suppressor NDRG1 in pancreatic cancer | The University of Sydney | \$199,684 |
| Ms Ann Livingstone | The costs, benefits and patient and clinician preferences of adjuvant immunotherapy in melanoma (Health Economics) | The University of Sydney | \$84,106 |
| Ms Xanthi Coskinas | Changes to design aspects of ongoing randomised controlled trials (RCT) | The University of Sydney | \$64,057 |
| Ms Rachel Farber | Examination of the impact of shifting practice from plain film mammography to digital mammography | The University of Sydney | \$34,723 |
| Mr Nicholas Keilar | 2018 Equipment Grant | Centenary Institute of Cancer Medicine and Cell Biology | \$14,051 |